Q3 2024 Curis Inc Earnings Call Transcript
Key Points
- Curis Inc (CRIS) reported encouraging early data from their PCNSL study, showing three complete responses and two partial responses among 10 evaluable patients.
- The company is actively engaging with regulatory authorities to define the registrational path for Emavusertib, indicating progress towards potential approval.
- Curis Inc (CRIS) has shown promising results in their leukemia study, with six of 11 evaluable patients achieving an objective response.
- The company completed a registered direct offering and concurrent private placement, raising approximately $10.8 million, strengthening their financial position.
- Curis Inc (CRIS) expects its existing cash and cash equivalents to support planned operations into mid-2025, providing a stable financial outlook.
- Curis Inc (CRIS) reported a net loss of $10.1 million for the third quarter of 2024, indicating ongoing financial challenges.
- Research and development expenses remain high, with $9.7 million spent in the third quarter of 2024, reflecting significant ongoing investment needs.
- The company faces challenges in patient enrollment for their triplet study, impacting the progress of clinical trials.
- There is uncertainty regarding the FDA's approval path for Emavusertib, which could affect the timeline for bringing the drug to market.
- Curis Inc (CRIS) must prioritize between multiple promising programs, which could lead to resource allocation challenges.
Good morning, ladies and gentlemen and welcome to the Curis third quarter, 2024 business update call at this time. All lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, you require immediate assistance. Please press star zero for the operator. This call is being recorded on Thursday, November 14, 2024. I would now like to turn the conference over to Diantha Duvall. Curis Chief Financial Officer. Please go ahead.
Thank you and welcome to Curis third quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the investors section of our website at www.Curis.com to find our third quarter, 2024 business update, press release and related financial tables. I would also like to remind everyone that during the call we will be making forward-looking statements which are based upon our current expectations and beliefs. These statements are subject to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
